Event Coverage

Is real-world evidence ready to reshape HTA and market access in 2026? 🔍 At GetReal Conference 2026, leaders from industry, regulators and payers will outline practical steps to transform evidence generation—covering advanced analytics, digital data capture, patient-centered outcomes and the implications for reimbursement and policy. Key discussions include improving data quality, fostering cross‑stakeholder collaboration, and integrating AI-driven evidence into decision-making. #SyenzaNews #HealthTech #HealthEconomics #MarketAccess #DigitalTransformation

Ready to see how Real‑World Evidence is reshaping healthcare decisions? 🔍💡 Leaders from industry, regulators, and academia at the RWE Conference shared advances in data integration (EHRs, wearables), AI-enabled analytics, and pragmatic study designs that are speeding up regulatory approvals and strengthening market access strategies. Key case studies and practical recommendations show how to turn real-world data into actionable, patient-centric insights. #SyenzaNews #digitalhealth #HealthTech #MarketAccess #innovation

How will the World Orphan Drug Congress 2026 change access to life‑saving rare‑disease therapies? 🔬🌍 Industry leaders and policymakers are set to explore faster regulatory pathways, sustainable pricing models, and public‑private partnerships to scale manufacturing and put patient‑centric trials at the center of access strategies. These takeaways point to practical steps for improving global equity in orphan drug availability. Read the full article for the key insights and what they mean for industry, payers and patients. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #healthcarepolicy

Who will bridge the gap between breakthrough orphan drugs and the patients who need them? 🧬 At the World Orphan Drug Congress 2026, leaders are set to share how adaptive trials, regulatory incentives, and patient-centric design are speeding rare-disease innovation while confronting commercialization and reimbursement challenges. The article highlights practical strategies for biotech, regulators, and payers to accelerate development and improve access. Read the full insights to see what’s changing—and what your organisation should do next. #SyenzaNews #drugdevelopment #pharmaceuticals #innovation #MarketAccess

Can policy and innovation finally close the access gap for rare-disease patients? 🧬 At the World Orphan Drug Congress 2026, leaders are set to outline practical solutions — from adaptive regulatory pathways and outcome‑based reimbursement to public–private partnerships — that could speed orphan drug availability while balancing costs and evidence needs. This article distills the conference’s key takeaways, case studies, and action points for industry, payers, and patient groups. Read the full piece to see which strategies are ready to scale and what stakeholders should prioritize next. #SyenzaNews #drugdevelopment #regulatoryaffairs #MarketAccess #healthcarepolicy

What will it take to bring more orphan drugs to patients faster? 💡 The World Orphan Drug Congress 2026 is set to show how regulatory harmonization, adaptive trial designs, patient-centric evidence and innovative financing are coming together to shorten development timelines and improve market access for rare therapies. These insights will likely offer practical takeaways for developers, regulators, payers and patient advocates. Read the full article for actionable strategies and next steps at the Congress. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #innovation

How will HTA evolve to shape access and value for tomorrow’s health technologies? 🔍🌍 HTAi 2026 is set to highlight shifts toward patient-centred methods, greater use of real‑world evidence, and international alignment that could speed market access and influence reimbursement decisions. These trends offer practical implications for payers, manufacturers and policy-makers aiming to future‑proof HTA strategies. Read the full coverage to see the anticipated key takeaways and actionable next steps. #SyenzaNews #HealthEconomics #HealthTechnology #MarketAccess #healthcarepolicy

How will HTAi 2026 reshape health technology assessment globally? 🔍 Key themes from the annual meeting—greater use of real‑world evidence, stronger patient and stakeholder engagement, and new frameworks for assessing digital and combination therapies—signal practical shifts in methods, policy, and market access that stakeholders need to track. Read more for session highlights, expert perspectives, and what organisations should do next to stay ahead. #SyenzaNews #HealthTechnology #HealthEconomics #MarketAccess #healthcarepolicy

Is Lisbon the next European hub for healthcare innovation? 📍🚀 From a surge in HealthTech startups and AI-driven care pilots to stronger public–private partnerships and EU-backed funding, Lisbon is turning research excellence into scalable healthcare solutions. Read the full piece for the trends, opportunities, and practical takeaways shaping the region’s health ecosystem. #SyenzaNews #HealthcareInnovation #HealthTech #innovation #DigitalTransformation